BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34670665)

  • 1. [Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway].
    Zhu H; Liu D; Deng S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Oct; 37(10):891-896. PubMed ID: 34670665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
    Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
    Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
    Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
    Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The roles of holothurian glycosaminoglycan combined with cisplatin on proliferation and chemotherapeutic response in A549 human lung adenocarcinoma cell].
    Jin Q; Zhu XH; Lin CZ; Zhang H; Cao YW; Ding XQ; Lyu ZH
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):252-257. PubMed ID: 29730910
    [No Abstract]   [Full Text] [Related]  

  • 5. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
    Xie C; Pan Y; Hao F; Gao Y; Liu Z; Zhang X; Xie L; Jiang G; Li Q; Wang E
    APMIS; 2014 Dec; 122(12):1251-8. PubMed ID: 25131138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Synergistic Antitumor Effect of Amorphigenin Combined with Cisplatin in Human Lung Adenocarcinoma A549/DDP Cells].
    Zhong H; Zuo Y; Wu X; Peng Y; He H; Yang J; Guan C; Xu Z
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):805-812. PubMed ID: 27978865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Increased expression of acetaldehyde dehydrogenase in cisplatin-resistant human lung adenocarcinoma A549/DDP cells].
    He J; Song X; Yu L; Li J; Qiao Z; Jiu R; Yu B; Liu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):625-9. PubMed ID: 25940289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
    Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M
    Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propofol Improves Sensitivity of Lung Cancer Cells to Cisplatin and Its Mechanism.
    Huang Y; Lei L; Liu Y
    Med Sci Monit; 2020 Mar; 26():e919786. PubMed ID: 32225124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Buzhong yiqi decoction containing serum reversed resistance of A549/DDP to cisplatin and its effect on the expression of survivin: an experimental research ].
    Yi JL; Wang Y; Jing H; Shi YT; Liu CY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Oct; 34(10):1250-5. PubMed ID: 25509271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Examination of resistance of lung adenocarcinoma cells to cisplatin by technetium-99m methoxyisobutyl isonitrile].
    Hu S; Hu CP; Liang CH
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1493-8. PubMed ID: 16061030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of galectin-1 gene silencing on resistance to cisplatin in human lung adenocarcinoma A549 cells.
    Zhang L; Liu X; Tang Z; Li X; Wang G
    Biomed Pharmacother; 2016 Oct; 83():265-270. PubMed ID: 27392028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
    Qin X; Liu C; Zhou Y; Wang G
    Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1366-72. PubMed ID: 20937224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and significance of IKBKB in pulmonary adenocarcinoma A549 cells and its cisplatin-resistant variant A549/DDP].
    Qi K; Li Y; Li X; Zhang F; Shao Y; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2014 May; 17(5):363-8. PubMed ID: 24854552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of sorafenib on the A549/DDP human lung adenocarcinoma cell line in vitro.
    Chen XQ; Wang YL; Li ZY; Lin TY
    Mol Med Rep; 2014 Jul; 10(1):347-52. PubMed ID: 24788469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.